Literature DB >> 33596225

"Yes, I'm interested in taking PrEP!": PrEP interest among women respondents to the European community-based survey "Flash! PrEP in Europe".

Rosemary M Delabre1, Adeline Bernier1, Flor Sánchez2, Antoine Vilotitch3,4, Sophocles Chanos5, Maria Luisa Cosmaro6, Harriet Langanke7, Coline Mey8, Cary James9, Sascha B Duken10, Vincent Schlegel8, Richard Stranz8, Kai J Jonas11, Bruno Spire3,8, Daniela Rojas Castro1,3.   

Abstract

The World Health Organization recommends pre-exposure prophylaxis (PrEP) for all populations at substantial risk of HIV infection, including women. However, data regarding PrEP interest among women is lacking, particularly in Europe. Factors associated with interest in using PrEP were assessed among women respondents to the Flash! PrEP in Europe (FPIE) survey. This community-based cross-sectional study, conducted in 12 European countries, aimed to assess PrEP knowledge and interest. "High objective risk" (HOR) was assessed using established risk criteria following EACS and CDC guidelines. Factors associated with interest in using PrEP were assessed in univariable and multivariable logistic regression models. Among 678 women, 12.5% (n = 85) were considered at HOR, 46.8% (n = 317) indicated prior PrEP knowledge and 18.0% (n = 122) reported interest in using PrEP. Among women at HOR, 40.0% (n = 34) were interested in PrEP. Factors significantly associated with PrEP interest in the final multivariable model were: younger age (18-29 years) (aOR 1.91[95CI: 1.07; 3.41]), bad self-perceived financial status (1.84[1.09; 3.11]), migrant status (south to north) (2.87[1.05; 7.89]), single or dating relationship status (1.93[1.23; 3.03]), sexual abuse history (1.86[1.17; 2.97]), "rather high"/ "high" self-perceived HIV risk (3.21[1.32; 7.81]), and HOR (2.49[1.42; 4.35]). These results show that women at HOR and those who perceived themselves to be at high risk are interested in using PrEP. There is a critical need for targeted information and improved access to PrEP to increase uptake of this HIV prevention tool to meet PrEP interest among women.

Entities:  

Mesh:

Year:  2021        PMID: 33596225      PMCID: PMC7888674          DOI: 10.1371/journal.pone.0246037

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  56 in total

1.  Associations between intimate partner violence, violence-related policies, and HIV diagnosis rate among women in the United States.

Authors:  Tiara C Willie; Jamila K Stockman; Rachel Perler; Trace S Kershaw
Journal:  Ann Epidemiol       Date:  2018-07-25       Impact factor: 3.797

2.  A Risk Assessment Tool for Identifying Pregnant and Postpartum Women Who May Benefit From Preexposure Prophylaxis.

Authors:  Jillian Pintye; Alison L Drake; John Kinuthia; Jennifer A Unger; Daniel Matemo; Renee A Heffron; Ruanne V Barnabas; Pamela Kohler; R Scott McClelland; Grace John-Stewart
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

3.  Gender based violence as a risk factor for HIV-associated risk behaviors among female sex workers in Armenia.

Authors:  Delia L Lang; Laura F Salazar; Ralph J DiClemente; Karine Markosyan
Journal:  AIDS Behav       Date:  2013-02

4.  Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education.

Authors:  Matthew J Mimiaga; Patricia Case; Carey V Johnson; Steven A Safren; Kenneth H Mayer
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

5.  Awareness of Pre-exposure Prophylaxis for HIV, Willingness to Use It and Potential Barriers or Facilitators to Uptake Among Men Who Have Sex with Men in Spain.

Authors:  L Ferrer; C Folch; P Fernandez-Davila; A Garcia; A Morales; J Belda; A R Susperregui; J Casabona
Journal:  AIDS Behav       Date:  2016-07

6.  Participants' Explanations for Nonadherence in the FEM-PrEP Clinical Trial.

Authors:  Amy Corneli; Brian Perry; Kevin McKenna; Kawango Agot; Khatija Ahmed; Jamilah Taylor; Fulufhelo Malamatsho; Jacob Odhiambo; Joseph Skhosana; Lut Van Damme
Journal:  J Acquir Immune Defic Syndr       Date:  2016-04-01       Impact factor: 3.731

Review 7.  Optimizing Delivery of HIV Preexposure Prophylaxis for Women in the United States.

Authors:  Erika Aaron; Cori Blum; Dominika Seidman; Mary Jo Hoyt; Joanne Simone; Meg Sullivan; Dawn K Smith
Journal:  AIDS Patient Care STDS       Date:  2018-01       Impact factor: 5.078

Review 8.  Pre-exposure prophylaxis for HIV prevention in women: current perspectives.

Authors:  Charlene A Flash; Sannisha K Dale; Douglas S Krakower
Journal:  Int J Womens Health       Date:  2017-05-31

9.  Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions.

Authors:  K Rivet Amico; Catalina Ramirez; Margaret R Caplan; Brooke Ee Montgomery; Jennifer Stewart; Sally Hodder; Shobha Swaminathan; Jing Wang; Noshima Y Darden-Tabb; Marybeth McCauley; Kenneth H Mayer; Timothy Wilkin; Raphael J Landovitz; Roy Gulick; Adaora A Adimora
Journal:  J Int AIDS Soc       Date:  2019-03       Impact factor: 5.396

10.  Knowledge, Attitudes, and Experiences of HIV Pre-Exposure Prophylaxis (PrEP) Trial Participants in Botswana.

Authors:  Lauren Toledo; Eleanor McLellan-Lemal; Faith L Henderson; Poloko M Kebaabetswe
Journal:  World J AIDS       Date:  2015-02-12
View more
  1 in total

1.  PrEP in the Context of Other HIV Risk Reduction Strategies Among Men Who Have Sex with Men: Results from the Flash! PrEP in Europe Survey.

Authors:  Marion Di Ciaccio; Rosemary M Delabre; Antoine Vilotitch; Giulio Maria Corbelli; Virginie Villes; Alejandro Ros Sánchez; Paul Zantkuijl; Holger Sweers; Flor Sanchez; Michael Meulbroek; Gus Cairns; Adeline Bernier; Jade Ghosn; Luìs Miguel Carvalho Rocha; Maria Luisa Cosmaro; Sascha Béla Duken; Monica Dan; Vincent Schlegel; Richard Stranz; Kai J Jonas; Bruno Spire; Daniela Rojas Castro
Journal:  Arch Sex Behav       Date:  2022-06-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.